Skip to main content

Advertisement

SpringerLink
Log in

Surveillance in Barrett’s Esophagus: An Audit of Practice

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Goals

Determine the rates of follow-up, incident rate of cancer during surveillance, and changes in pathologic grade of patients with Barrett’s esophagus during surveillance in a gastroenterology practice without a formal surveillance program.

Background

Barrett’s esophagus is a pre-malignant condition. Surveillance endoscopy (SE) is recommended in order to detect and treat high-grade dysplasia and esophageal adenocarcinoma early and prevent deaths. SE has not been shown to have mortality benefit and several studies have questioned its cost-effectiveness. Most gastroenterology practices do not have a surveillance program for Barrett’s esophagus. The few that exist are only in very specialized and funded programs. Little information exists on outcomes in patients with Barrett’s esophagus outside of these well-structured surveillance programs.

Study

A retrospective analysis of a cohort of patients with Barrett’s esophagus diagnosed and surveyed between 1995 and 2005 at a Veterans Affairs medical center. Data were collected on age, body mass index, and race. Patients who missed their SE by 6 months or more and those that missed their SE by twice the recommended intervals or more were identified and analyzed for changes in pathologic grades.

Results

A total of 472 patients were diagnosed with Barrett’s esophagus or had SE between 1995 and 2005. Three hundred and five patients only had one endoscopy and biopsy. They did not have follow-up surveillance endoscopies and biopsies. Two patients were excluded from the final analysis: one had an esophagectomy after an index diagnosis of high-grade dysplasia, and one had a diagnosis of esophageal adenocarcinoma 2 days after an initial impression of Barrett’s esophagus. There were 165 patients with Barrett’s metaplasia or dysplasia who had SE more than once and were included in the final analysis. Overall, 53.3% had no change in pathologic grade, 35.2% regressed to a lower pathologic grade, and 11.5% progressed to a higher grade. None (0/165, 0%) progressed to esophageal adenocarcinoma; 3.6% (6/165) progressed to high-grade dysplasia and 11.5% (19/165) regressed to normal mucosa. Forty-four patients missed their SE by 6 months or more. Of these, 50% regressed, 40.9% had no change, and 9.1% progressed. Four patients regressed to normal mucosa, one progressed to high-grade dysplasia and none progressed to esophageal adenocarcinoma. Twenty-three patients missed their SE by twice the recommended intervals or more. Of these, 60.9% regressed, 34.8% did not change, and 4.3% progressed. None progressed to esophageal adenocarcinoma or high-grade dysplasia but three regressed to normal mucosa. After adjusting for age and body mass index, patients with low-grade dysplasia are nearly seven times more likely to miss their endoscopy by twice the recommended intervals or more (OR 6.56, P-value 0.03).

Conclusions

Most veteran patients with Barrett’s esophagus do not undergo surveillance endoscopies. Veteran patients with Barrett’s esophagus undergoing SE rarely progress to high-grade dysplasia or esophageal adenocarcinoma. Veteran patients with Barrett’s esophagus who have longer SE up to twice the recommended intervals because they missed their scheduled SE did not have a worse outcome when compared to the general Barrett’s esophagus surveillance group. Veteran patients with low-grade dysplasia are most likely to miss their SE by twice the recommended intervals or more, though the reason for this is unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797. doi:10.1111/j.1572-0241.2008.01835.x.

    Article  PubMed  Google Scholar 

  2. Bresalier R. Barrett’s metaplasia: defining the problem. Semin Oncol. 2005;32:21–24. doi:10.1053/j.seminoncol.2005.07.021.

    Article  PubMed  CAS  Google Scholar 

  3. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831. doi:10.1053/j.gastro.2005.08.053.

    Article  PubMed  Google Scholar 

  4. Haggitt RC, Tryzelaar J, Ellis H, et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett’s) esophagus. Am J Clin Pathol. 1978;90:1–5.

    Google Scholar 

  5. Haggitt RC. Barrett’s esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982–993. doi:10.1016/0046-8177(94)90057-4.

    Article  CAS  PubMed  Google Scholar 

  6. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in BE. Gut. 1991;32:1441–1446. doi:10.1136/gut.32.12.1441.

    Article  CAS  PubMed  Google Scholar 

  7. Streitz JM Jr, Ellis FH Jr, Tilden RL, et al. Endoscopic surveillance of Barrett’s esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol. 1998;93:911–915. doi:10.1111/j.1572-0241.1998.00275.x.

    Article  PubMed  Google Scholar 

  8. Eloubeidi MA, Homan RK, Martz MD, et al. A cost analysis of outpatient care for patients with Barrett’s esophagus in a managed care setting. Am J Gastroenterol. 1999;94:2033–2036. doi:10.1111/j.1572-0241.1999.01274.x.

    Article  CAS  PubMed  Google Scholar 

  9. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett’s cancer. Gut. 1996;39:574–579. doi:10.1136/gut.39.4.574.

    Article  CAS  PubMed  Google Scholar 

  10. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett’s esophagus. Am J Gastroenterol. 1988;83:291–294.

    CAS  PubMed  Google Scholar 

  11. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043–2053. doi:10.1111/j.1572-0241.1999.01276.x.

    Article  CAS  PubMed  Google Scholar 

  12. Provenzale D, Kemp JA, Arora S, et al. A guide for surveillance of patients with Barrett’s esophagus. Am J Gastroenterol. 1994;89:670–680.

    CAS  PubMed  Google Scholar 

  13. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost utility analysis. Ann Intern Med. 2003;138:176–186.

    PubMed  Google Scholar 

  14. Somerville M, Garside R, Pitt M, et al. Surveillance of Barrett’s oesophagus: is it worthwhile? Eur J Cancer. 2008;44:588–599. doi:10.1016/j.ejca.2008.01.015.

    Article  CAS  PubMed  Google Scholar 

  15. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633–640. doi:10.1053/gast.2002.31879.

    Article  PubMed  Google Scholar 

  16. Cooper GS. Endoscopic screening and surveillance for Barrett’s esophagus: can claims data determine its effectiveness? Gastrointest Endosc. 2003;57(7):914–915. doi:10.1016/S0016-5107(03)70029-7.

    Article  PubMed  Google Scholar 

  17. Dellon ES, Shaheen NJ. Does screening for Barrett’s esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol. 2005;23:4478–4482. doi:10.1200/JCO.2005.19.059.

    Article  PubMed  Google Scholar 

  18. Shaheen NJ, Dulai GS, Ascher B, et al. Effect of a new diagnosis of Barrett’s esophagus on insurance status. Am J Gastroenterol. 2005;100:577–580. doi:10.1111/j.1572-0241.2005.41422.x.

    Article  PubMed  Google Scholar 

  19. Falk GW, Ours TM, Richter J. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc. 2000;52:197–203. doi:10.1067/mge.2000.107728.

    Article  CAS  PubMed  Google Scholar 

  20. Gross GP, Canto MI, Hixson J, et al. Management of Barrett’s esophagus: a national study of practice patterns and cost implications. Am J Gastroenterol. 1999;94(12):3440–3447. doi:10.1111/j.1572-0241.1999.01606.x.

    Article  CAS  PubMed  Google Scholar 

  21. Rubenstein JH, Saini SD, Kuhn L, et al. Influence of malpractice history on the practice of screening and surveillance for Barrett’s esophagus. Am J Gastroenterol. 2007;102:1–8. doi:10.1111/j.1572-0241.2007.01057.x.

    Article  Google Scholar 

  22. Yousef F, Cardwell C, Cantwell M, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249. doi:10.1093/aje/kwn121.

    Article  PubMed  Google Scholar 

  23. Thomas T, Abrams KR, De Caestecker JS, et al. Meta analysis: cancer risk in Barrett’s esophagus. Aliment Pharmacol Ther. 2007;26:1465–1477.

    CAS  PubMed  Google Scholar 

  24. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119:333–338. doi:10.1053/gast.2000.9302.

    Article  CAS  PubMed  Google Scholar 

  25. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888–1895. doi:10.1111/j.1572-0241.2002.05910.x.

    Article  PubMed  Google Scholar 

  26. Deviere J, Buset M, Dumonceau JM, et al. Regression of Barrett’s epithelium with omeprazole. N Engl J Med. 1989;320:1497–1498.

    Article  CAS  PubMed  Google Scholar 

  27. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett’s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc. 1996;44:700–705. doi:10.1016/S0016-5107(96)70055-X.

    Article  CAS  PubMed  Google Scholar 

  28. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett’s esophagus. Am J Gastroenterol. 1999;94:3420–3426. doi:10.1111/j.1572-0241.1999.01603.x.

    Article  CAS  PubMed  Google Scholar 

  29. Wilkinson SP, Biddlestone L, Gore S, et al. Regression of columnar-lined (Barrett’s) esophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther. 1999;13:1205–1209. doi:10.1046/j.1365-2036.1999.00593.x.

    Article  CAS  PubMed  Google Scholar 

  30. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–1399. doi:10.1053/j.gastro.2006.08.032.

    Article  PubMed  Google Scholar 

  31. Horwhat JD, Baroni D, Maydonovitch C, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol. 2007;102:497–506. doi:10.1111/j.1572-0241.2006.00994.x.

    Article  PubMed  Google Scholar 

  32. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term non-surgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619. doi:10.1053/gast.2001.25065.

    Article  CAS  PubMed  Google Scholar 

  33. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99:1877–1883. doi:10.1111/j.1572-0241.2004.30228.x.

    Article  CAS  PubMed  Google Scholar 

  34. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust. 2004;180(8):387–391.

    PubMed  Google Scholar 

  35. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–498. doi:10.1016/j.gie.2005.06.047.

    Article  PubMed  Google Scholar 

  36. Montgomery E. Is there a way for pathologists to decrease interobserver variability in the diagnosis of dysplasia? Arch Pathol Lab Med. 2005;129:174–176.

    PubMed  Google Scholar 

  37. Yearsley MM, Haggitt RC, Taylor SL, et al. Reinterpretation of high-grade dysplasia in Barrett’s esophagus: a multicenter international phase III trial in 485 patients. Mod Pathol. 2006;19(suppl 19):A569. (Abstract).

    Google Scholar 

  38. Downs-Kelly E, Mendelin JE, Bennett AE, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies. Am J Gastroenterol. 2008;103:2333–2340. doi:10.1111/j.1572-0241.2008.02020.x.

    Article  PubMed  Google Scholar 

  39. Hanna S, Rastogi A, Weston AP, et al. Detection of Barrett’s esophagus after endoscopic healing for erosive esophagitis. Am J Gastroenterol. 2006;101:1416–1420. doi:10.1111/j.1572-0241.2006.00631.x.

    Article  PubMed  Google Scholar 

  40. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124:47–56. doi:10.1053/gast.2003.50008.

    Article  CAS  PubMed  Google Scholar 

  41. Vaughan TL, Dong LM, Blount P, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6:945–952. doi:10.1016/S1470-2045(05)70431-9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Loma Linda Veterans Health Care System, 11201 Benton Street, Loma Linda, CA, 92357, USA

    Adewale Ajumobi

  2. Epidemiology and Biostatistics, Loma Linda University, Evans Hall, 24785 Stewart Street, Loma Linda, CA, 92350, USA

    Khaled Bahjri

  3. Division of Gastroenterology, Loma Linda Veterans Health Care System, 11201 Benton Street, Loma Linda, CA, 92357, USA

    Christian Jackson & Ronald Griffin

Authors
  1. Adewale Ajumobi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khaled Bahjri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald Griffin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adewale Ajumobi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ajumobi, A., Bahjri, K., Jackson, C. et al. Surveillance in Barrett’s Esophagus: An Audit of Practice. Dig Dis Sci 55, 1615–1621 (2010). https://doi.org/10.1007/s10620-009-0917-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-009-0917-y

Keywords

Search

Navigation